Curriculum Vitae

am EXECUTIVE CONSULTING

Associate Partner at Fidelio Healthcare Partners GmbH & Co. KG, Limburg

Permanent mandate at MIP Pharma Holding GmbH, Homburg
Since 2025 Senior Advisor
2020–2025 Chairman of the Advisory Board (Supervisory Board under German GmbH law)

Member of the Supervisory Board of Mutares SE & Co. KGaA (then listed in the SDAX), Munich
2019–2025 Deputy Chairman of the Supervisory Board
2019–2025 Chairman of the Audit Committee

Member of the Supervisory Board of Mutares Management SE, Munich

Director/Senior Advisor at Arthur D. Little GmbH, Frankfurt

Executive Board Member for Production and Development at STADA Arzneimittel AG (then listed in the MDAX), Bad Vilbel

• Joint executive responsibility for managing a publicly listed, globally operating MDAX company with approx. €2 billion in revenue and over 8,000 employees worldwide.
• Responsibility for Production, Development (incl. Regulatory Affairs), Procurement and Supply Chain, Quality Management, and Portfolio Management (incl. In-Licensing).
• Implementation of the company-wide cost-efficiency program “Build the Future,” including the establishment of new corporate governance in operations.

Demonstrably very successful: Significant increases in key STADA Group metrics such as Revenue +25%, Operating Profit +34%, EBITDA +29%, Group Net Income +32% (H1/2013 vs. H1/2010), and Share Price >+40% (06.08.2013 vs. 15.09.2010).

Longtermin Executive Board Advisory at STADA Arzneimittel AG on strategic corporate development and project-based issues, including:

• Strategic positioning in individual markets and segments (1993–2010)
• Development of the cost-efficiency program “STADA – Build the Future” (2009–2010)
• Due diligence and contract negotiations for corporate and product acquisitions and In-Licensing projects (1993–2010)
• Monitoring of health policy developments in Germany and key EU markets and creation of related policy papers

Additionally, temporary operational management roles at STADA Group (from 2005 as Vice President, from 2008 as Senior Vice President):

• Head of Branded Business Germany (STADA GmbH) with approx. €100 million in OTC market sales (2009–2010)
• Head of Corporate Communications incl. Investor Relations (2000–2010)
• Country Manager Switzerland (1995–1999)
• Lead of project team for operational integration of an acquired product portfolio (1995)
• Head of Generics Business Germany (STADApharm GmbH) (1995)

Various management positions at STADA Arzneimittel AG, including:

• Head of Corporate Development (1989–1993)
• Head of Business Planning and Marketing Services (incl. Market Research and Customer Service Center) (1988–1993)
• Strategic Planning Generics (1987–1988)
• Product Management OTC (1985–1987)

PhD in Natural Science

Research Associate at the Chair of Pharmaceutical Technology, Institute of Pharmacy, Johannes Gutenberg University Mainz

Licensed as a Pharmacist

Studies in Pharmacy at Johannes Gutenberg University Mainz

Born in Koblenz